Undifferentiated Connective Tissue Disease, Mixed Connective Tissue Disease, and Overlap Syndromes
Özet
Connective tissue diseases (CTDs) are systemic autoimmune diseases that can present with a wide variety of clinical features. If the disease symptoms do not meet the criteria for a specific CTD but still have the clinical manifestations of a systemic autoimmune disease, it is called undifferentiated CTD; if there are findings of one or more specific CTDs, it is called overlap syndrome. Mixed connective tissue disease (MCTD) is a type of CTD that has distinctive clinical findings in the presence of anti-U1 RNP antibodies. Cardiovascular abnormalities such as increased atherosclerosis, dyslipidemia, and increased systolic blood pressure are seen in all three types of CTD. Pericarditis and pulmonary hypertension are cardiac abnormalities that require special attention in MCTD. In this section, the cardiac involvement along with the management methods of these three CTDs will be reviewed.
Konnektif doku hastalıkları (KDH) geniş çeşitlilikte klinik görünümle ortaya çıkabilen sistemik otoimmun hastalıklardır. Eğer hastalık semptomları spesifik bir KDH kriterini karşılamıyor fakat sistemik bir KDH’na işaret eden bulgular gösteriyorsa andifferansiye KDH; bir veya daha fazla spesifik KDH’ya ait bulgular mevcutsa çakışma sendromu olarak isimlendirilmektedir. Miks konnektif doku hastalığı (MKDH) ise anti-U1 RNP antikorları mevcudiyetinde kendine ait klinik bulguları olan bir KDH çeşididir. Artmış ateroskleroz, dislipidemi, artmış sistolik kan basıncı gibi kardiyovasküler anormalliklere bu üç KDH tipinde de rastlanmaktadır. Perikardit ve pulmoner hipertansiyon MKDH’ da özellikle dikkat edilmesi gereken kardiyak anormalliklerdir. Bu bölümde bu üç KDH’daki kardiyak tutulumlar ve yaklaşım şekilleri incelenecektir.
Referanslar
Marwa K, Anjum F. Undifferentiated Connective Tissue Disease. [Updated 2023 Mar 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572061/
LeRoy EC, Maricq HR, Kahaleh MB. Undifferentiated connective tissue syndromes. Arthritis Rheum. 1980;23(3):341-343. doi: 10.1002/art.1780230312.
Williams HJ, Alarcon GS, Joks R, et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol. 1999;26(4):816-25. PMID: 10229402.
Mosca M, Tani C, Vagnani S, et al. The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun. 2014;48-49:50-2. doi: 10.1016/j.jaut.2014.01.019.
Herrick A. Overlap/undifferentiated syndromes. In: Watts RA, Conaghan PG, Denton C, et al. (Eds). Oxford Textbook of Rheumatology 4th Ed. 2013. Pgs:1069-1078.
Soltesz P, Kerekes G, De´r H et al. Comparative assessment of vascular function in autoimmune rheumatic diseases:considerations of prevention and treatment. Autoimmun Rev. 2011;10:416-425. doi: 10.1016/j.autrev.2011.01.004.
Murdaca G, Colombo BM, Cagnati P et al. Endothelial dysfunction in rheumatic autoimmune diseases.Atherosclerosis 2012;224:309-317. doi: 10.1016/j.atherosclerosis.2012.05.013.
Laczik R, Soltesz P, Szodoray P, et al. Impaired endothelial function in patients with undifferentiated connective tissue disease: a follow-up study. Rheumatology (Oxford). 2014;53(11):2035-2043. doi: 10.1093/rheumatology/keu236.
Mosca, M, Virdis, A, Tani, C, et al. Vascular reactivity in patients with undifferentiated connective tissue diseases. Atherosclerosis. 2009;203:185-191. doi: 10.1093/rheumatology/keu236.
Zold E, Szodoray P, Nakken B et al. Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. Autoimmun Rev 2011;10:155-162. doi: 10.1016/j.autrev.2010.09.018.
D'Alto M, Riccardi A, Argiento P, et al. Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very early-early systemic sclerosis): a TDI study. Clin Exp Med. 2018;18(2):237-243. doi: 10.1007/s10238-017-0477-y.
Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology. 2006;45(Suppl 4):iv14–17. doi: 10.1093/rheumatology/kel312.
Parks JL, Taylor MH, Parks LP, et al. Systemic sclerosis and the heart. Rheum Dis Clin North Am. 2014;40:87–102. doi: 10.1016/j.rdc.2013.10.007.
Mosca M, Tani C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Pract Res Clin Rheumatol. 2007;21:1011-1023. doi: 10.1016/j.berh.2007.09.004.
Swaak AJ, van de Brink H, Smeenk RJ et al. Incomplete lupus erythematosus results of a multicenter study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology. 2001;40:89-94. doi: 10.1093/rheumatology/40.1.89.
Lunardi F, Balestro E, Nordio B et al. Undifferentiated connective tissue disease presenting with prevalent interstitial lung disease: case report and review of literature. Diagn Pathol. 2011;6:50. doi: 10.1186/1746-1596-6-50.
Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14:37-44. doi: 10.1016/j.molmed.2007.11.004.
Distler JH, Feghali-Bostwick C, Soare A, et al. Frontiers of antifibrotic therapy in systemic sclerosis. Arthritis Rheumatol. 2016. doi:10.1002/art.39865.
Gunnarsson R, Molberg O, Gilboe IM et al. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis 2011;70:1047-1051. doi: 10.1136/ard.2010.143792.
Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52:148-59. doi: 10.1016/0002-9343(72)90064-2.
Oetgen WJ, Mutter ML, Lawless OJ, et al. Cardiac abnormalities in mixed connective tissue disease. Chest. 1983;83:185-188. doi: 10.1378/chest.83.2.185.
Hajas A, Szodoray P, Nakken B, et al. Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol 2013;40:1134-1142. doi: 10.3899/jrheum.121272.
Alpert MA, Goldberg SH, Singsen BH et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 1983;68:1182-1193. doi: 10.1161/01.cir.68.6.1182.
Langley RL, Treadwell EL. Cardiac tamponade and pericardial disorders in connective tissue diseases: case report and literature review. J Natl Med Assoc. 1994;86(2):149-153. PMID: 8169992.
Sharp GC, Singsen BH. Mixed connective tissue disease. In: MacCarty DJ, ed. Arthritis and Allied Conditions. 11th ed. New York, NY: Lea & Febiger; 1989:1080-1091.
Singsen BH, Bernstein BH, Korneich HK, et al. Mixed connective tissue disease in childhood. A clinical and serological survey. J Pediatr 1977;90:893-900. doi: 10.1016/s0022-3476(77)80555-6.
Leung WH, Wong KL, Lau CP, et al. Echocardiographic identification of mitral valvular abnormalities in patients with mixed connective tissue disease. J Rheumatol. 1990;17:485-488. PMID: 2348428.
Negoro N, Kanayama Y, Yasuda M, et al. Nuclear ribonucleoprotein immune complexes in pericardial fluid of a patient with mixed connective tissue disease. Arthritis Rheum. 1987;30:97-101. doi: 10.1002/art.1780300114.
Kumar MS, Smith M, Pischel KD. Case report and review of cardiac tamponade in mixed connective tissue disease. Arthritis & Rheumatism. 2006;55: 826-830. doi: 10.1002/art.22227.
Soltesz P, Bereczki D, Szodoray P, et al. Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease. Arthritis Res Ther 2010;12:R78. doi: 10.1186/ar2999.
Skagen K, Hetlevik SO, Zamani M, et al. Preclinical Carotid Atherosclerosis in Patients With Juvenile-Onset Mixed Connective Tissue Disease. J Stroke Cerebrovasc Dis. 2019;28(5):1295-1301. doi: 10.1016/j.jstrokecerebrovasdis.2019.01.027.
Sullivan WD, Hurst DJ, Harmon CE et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984;63:92-107. doi: 10.1097/00005792-198403000-00003.
Burdt MA, Hoffman RW, Deutscher SL et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 1999;42:899-909. doi: 10.1002/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L.
Wigley FM, Lima JA, Mayes M et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum. 2005;52:2125-32. doi: 10.1002/art.21131.
Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144(2):275-85. PMID: 7508683
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42–50. doi: 10.1016/j.jacc.2013.10.032.
Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138:1383–1394. doi: 10.1378/chest.10-0260.
Ungprasert P, Wannarong T, Panichsillapakit T, et al. Cardiac involvement in mixed connective tissue disease: a systematic review. Int J Cardiol. 2014;171(3):326-330. doi: 10.1016/j.ijcard.2013.12.079.
Stacher G, Merio R, Budka C, et al. Cardiovascular autonomic function, autoantibodies, and esophageal motor activity in patients with systemic sclerosis and mixed connective tissue disease. J Rheumatol. 2000;27:692–697. PMID: 10743810
Rakovec P, Kenda MF, Rozman B, et al. Panconductional defect in mixed connective tissue disease: association with Sjogren’s syndrome. Chest. 1982;81:257–259. doi: 10.1378/chest.81.2.257.
Adler Y, Finkelstein Y, Guindo J, et al. Colchicine treatment for recurrent pericarditis: a decade of experience. Circulation. 1998;97:2183–2185. doi: 10.1161/01.cir.97.21.2183.
Rich S. Prostacyclin and primary pulmonary hypertension. Ann Intern Med. 1994;121:463-464. doi: 10.7326/0003-4819-121-6-199409150-00012.
Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121(6):409-415. doi: 10.7326/0003-4819-121-6-199409150-00003.
Shinohara S, Murata I, Yamada H, et al. Combined effects of diltiazem and oxygen in pulmonary hypertension of mixed connective tissue disease. J Rheumatol. 1994;21(9):1763-1765. PMID: 7799364.
Sanchez O, Sitbon O, Jais X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130:182–189. doi: 10.1378/chest.130.1.182.
Iaccarino L, Gatto M, Bettio S, et al. Overlap connective tissue disease syndromes. Autoimmun Rev. 2013;12(3):363-73. doi: 10.1016/j.autrev.2012.06.004.
Prasad M, Hermann J, Gabriel SE, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol. 2015;12(3):168-76. doi: 10.1038/nrcardio.2014.206.
